Centre de Référence Maladies Rares

U1035 INSERM

Biotherapy of genetic diseases, inflammatory disorders and cancers (BMGIC)

FR: Biologie Fondamentale Appliquée à la Médecine

U1035Display navigation INSERM U1035! FR / EN

Julien SENESCHAL

Prof.head of ATIP-AVENIR team (Immuno-dermatology), julien.seneschal@chu-bordeaux.fr

BIOSKETCH

PUBMED

Julien Seneschal, is Professor in Dermatology in the department of dermatology and paediatric dermatology at the university hospital in Bordeaux. He has clinical interests in the management of inflammatory skin diseases such as psoriasis, atopic dermatitis, systemic sclerosis, cutaneous lupus and skin reactions associated with the use of biotherapies and small molecules.

He is director of the Immuno-dermatology team in the INSERM 1035 unit with special interests in the comprehension of the immune mechanisms leading to inflammatory skin diseases and vitiligo.

University

1997-2003

  • Medical education
    Poitiers University School of Medicine

2003-2008

  • Residency
    Bordeaux University school of Medicine Dermatology

2008

  • Board Certification in Dermatology and Medical Thesis

2007

  • Master’ degree
    University of Bordeaux: Microbiology-Immunology

2008-2010

  • Post-doctoral felloship
    Harvard Skin Disease Research Center: Department of Dermatology under the direction of professor Thomas S. Kupper

2011

  • Ph.D degree
    University of Bordeaux: Microbiology-Immunology

2011

  • Certification in Allergology and Clinical Immunology
    University of Bordeaux

Positions

2010-

  • Assistant-professor in the department of dermatology and Paediatric Dermatology

Member of Societies

  • Société Française de Dermatologie – 2012
  • Société de Recherche Dermatologique – 2012
  • European Society for Dermatological Research – 2012

PUBLICATIONS

1. J. Seneschal*, P.Duffau*, C.Nicco*, J.F.Viallard, J.L.Pellegrin, B.Weil, J.F.Moreau, F.Batteux*, P.Blanco*: Modulation of interferon-alpha secretion by activated platelets in systemic lupus erythematous.
Sci Transl Med. 2010; 47ra63 * equally contribution.
F1000Prime: Michael Croft: recommendation: very good
2. J.Seneschal, R.A.Clark, A. Gehad, Clare M. Baecher-Allan, T.S. Kupper. Human Epidermal Langerhans Cells Maintain Immune Homeostasis in Skin by Activating Skin Resident Regulatory T Cells. Immunity, 2012: 873-84
F1000Prime: Oscar Colegio & Rachel Rosenstein: recommendation: very good
3. J.Seneschal, X.Jiang, T.S. Kupper. Langerin+ Dermal DC, but Not Langerhans Cells, Are Required for Effective CD8-Mediated Immune Responses after Skin Scarification with Vaccinia Virus.
J Invest Dermatol. 2014; 134; 686-94
4. A.Bertolotti, K.Boniface, B.Vergier, M.D.Mossalayi, A.Taieb, K.Ezzedine, J.Seneschal: Type I Interferon signature in the initiation of the immune response in vitiligo.
Pigment Cell Melanom Res. 2014; 27: 398-4074.
5. C. Jacquemin*, N. Schmitt*, C. Contin-Bordes*, Y. Liu, P. Narayanan, J. Seneschal, T. Maurouard, D. Dougall, E. Spence Davizon, H. Dumortier, I. Douchet, L. Raffray, C. Richez, E. Lazaro, P. Duffau, M.E. Truchetet, L. Khoryati, P. Mercié, L. Couzi, P. Merville, T. Schaeverbeke, J.F. Viallard, J.L. Pellegrin, J.F. Moreau, S. Muller, R.L. Coffman, V. Pascual, H. Ueno* and P. Blanco*. OX40 Ligand Contributes to the Pathogenesis of Autoiimunity by Promoting T follicular Helper Response.
Immunity, 2015: 1159-70
F1000Prime: Michael Croft: recommendation: very good

6. A. Poissonnier, D. Sanséau, M. Le Gallo, M. Malleter, N. Levoin, R. Viel, L. Morere, A. Penna, P. Blanco, A. Dupuy, F. Poizeau, A. Fautrel, J. Seneschal, F. Jouan, J. Ritz, E. Forcade, N. Rioux, C. Contin-Bordes, T. Ducret, A.M. Vacher, P.A. Barrow, R.J. Flynn, P. Vacher, P. Legembre. CD95-Mediated Calcium Signaling Promotes T Helper 17 Trafficking to Inflamed Organs in Lupus Prone Mice.
Immunity. 2016: 229-23
7. M. Larsabal, A. Marti, C. Jacquemin, J. Rambert, D. Thiolat, L. Dousset, A. Taieb, C. Dutriaux, S. Prey, K. Boniface, J. Seneschal. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo.
J Am Acad Dermatol 2017: 863-70
8. K. Boniface*, J. Seneschal*, M. Picardo, A. Taieb: Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy.
Clin Rev Allergy Immunol 2017 Jul 6 (* equally contribution)
9. C. Jacquemin, J. Rambert, S. Guillet, D. Thiolat, N Boukhedouni, MS Doutre, AS Darrigade, K Ezzedine, P. Blanco, A. Taieb, K. Boniface, J Seneschal. HSP70 potentiates interferon-alpha production by plasamcytoid dendritic cells : relevance for cutaneous lupus and vitiligo pathogenesis.
Br J Dermatol 2017: 1367-75
10. K. Boniface, C. Jacquemin, AS Darrigade, B. Dessarthe, C. Martins, N. Boukhedouni, C. Vernisse, A. Grasseau, D. Thiolat, J. Rabert, F/ Lucchese, A. Bertolotti, K. Ezzedine, A. Taieb, J. Seneschal. Vitiligo skin is imprinted with resident memory CD8 T cells expressing CXCR3.
J Invest Dermattol 2017 Sep 18

HONORS

  • « Claude Benezra » Award G.E.R.D.A (Groupe d’Etudes et de Recherches en Dermato-Allergologie), 2007
  • « Société de Recherche Dermatologique » Award, 2012
  • « European Foundation la Roche Posay » Award, 2012
  • « Charles Grupper » Léo Pharma Award, 2012
  • ESDR Academy for young leader in Dermatology, 2013

GRANTS

  • Lavoisier Grant: French Foreign Ministry Fellowship grant, 2008
  • Fondation René Touraine Award: European Fellowship grant, 2008
  • MD, PhD scholarship University of Bordeaux grant, 2008
  • SFR TransBiomed Grant, Bordeaux: grant, 2011
  • “Appel d’Offre Interne” grant CHU de Bordeaux, 2012
  • ATIP-AVENIR program (INSERM-CNRS), 2014
  • PHRC-I: METVI Project,

Back to organigramme

INSERM U1035! - University of Bordeaux
Work
146 rue Léo Saignat - PE building south zone, 4th floor
33000 Bordeaux
Aquitaine
France
Work +33 557 57 13 73/74
sarah.lesjean@inserm.fr